LUNAC Therapeutics

Spin-out from the University of Leeds developing next-generation oral and intravenous anticoagulants. Focuses on inhibiting activated Factor XII (FXIIa), a clotting enzyme involved in pathological thrombosis but not haemostasis — potentially eliminating bleeding risk of current anticoagulants. Has raised £4.75M including Northern Powerhouse Investment Fund (NPIF) and Epidarex Capital.